Tramadol Hydrochloride
Brand Names: Conzip
Methodology & AI Transparency ⓘ
Tramadol Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage conzip: is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.
- 2 Real-world patient consensus: Real-world cohort score of 92% across 5 de-identified Tramadol Hydrochloride entries.
- 3 Typical cash cost range: 30-day cash pricing ranges from $45.34 discount cash to $111.08 walk-in retail (NADAC $0.9096/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Tramadol Hydrochloride include orthostatic hypotension (5%), nausea (7.8%), headache (6.7%).
Ask our AI Specialists anything about Tramadol Hydrochloride
Tramadol Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage conzip: is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. CONZIP is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.
12.1 Mechanism of Action CONZIP contains tramadol, an opioid agonist, and an inhibitor of reuptake of norepinephrine and serotonin. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to mu-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. Opioid activity of tramadol is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to mu-opioid receptors.
Systemic exposure to Tramadol Hydrochloride reflects Approximately 49% to 61% enteral uptake across labeled Tramadol Hydrochloride strengths absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar tramadol hydrochloride conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 6–16 hour t½ intervals for Tramadol Hydrochloride half-life window (maximum serum exposure occurs 2–3 hours after tramadol hydrochloride dosing response profile).
Dosing protocols (300 mg/1 Tablet, Extended Release or 200 mg/1 Tablet, Extended Release or 50 mg/1 Tablet, Coated or 100 mg/1 Tablet, Film Coated, Extended Release or 50 mg/1 Tablet, Film Coated) balance efficacy (92.00% patient satisfaction across 5 logs) against nausea (7.8% of reports), headache (6.7% of reports), dizziness (6% of reports), with strict avoidance in history of severe allergic sensitivity to tramadol hydrochloride active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2025-12-29 tramadol hydrochloride labeling.
Synergistic sedative pharmacodynamics between Tramadol Hydrochloride and hypnotic agents elevate fall and respiratory risks.
Verify medication reconciliation lists so Tramadol Hydrochloride is not inadvertently duplicated with another opioid agonist.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Tramadol Hydrochloride active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2025-12-29 Tramadol Hydrochloride labeling
Logged Side-Effect Incidence (5 Reports)
Tramadol Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tramadol Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute: What a 344-Participant Study Found This pooled analysis reinforces the efficacy profile of CTC versus tramadol and, given that CTC permits lower daily tramadol dosing and thereby reduces unnecessary opioid use, this highlights its improved benefit/risk profile... Drugs in R&D • 2024-06-15 • Phase III Randomized Trial | N = 344 | 93/100 | PMID 38874739 ↗ |
| New Insights on Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following: What a 637-Participant Study Found Celecoxib-tramadol co-crystal was associated with reduced rescue medication use and an acceptable tolerability profile compared with tramadol or celecoxib alone in adults with acute, moderate-to-severe, postoperative pain. Pain practice : the official journal of World Institute of Pain • 2024-11-15 • Phase III Randomized Trial | N = 637 | 93/100 | PMID 38956758 ↗ |
| Managing Postoperative pain: Can HSK21542 Make a Real Difference? (What New Research Reveals) Grade ≥3 treatment-emergent side effects occurred in eight (5.9%) and three (2.3%) patients in the HSK21542 arm of HSK21542-301 and HSK21542-303, respectively. Nature communications • 2025-05-24 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40413233 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of twice-daily tramadol hydrochloride bilayer Sustained-release tramadol tablets with an immediate-release component are effective and well tolerated for managing postherpetic neuralgia. Pain practice : the official journal of World Institute of Pain • 2023-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36478501 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of co-crystal of tramadol-celecoxib (CTC) in acute Although the study did not meet its primary endpoint, CTC 200 mg showed a clinically relevant improvement in overall. European journal of pain (London, England) • 2022-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35974668 ↗ |
Tramadol Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.9096/unit (~$27.29/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $111.08 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $45.34 / mo | View logs ↓ |
Tramadol Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tramadol Hydrochloride RxNorm Concept ID | 1148478 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.9096 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $111.08 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $45.34 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tramadol Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Tramadol Hydrochloride: FDA labeling (2025-12-29, NDC 68025-071), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tramadol Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.